News from amplyx pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 03, 2020, 08:00 ET Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Oct 16, 2020, 08:00 ET Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Sep 14, 2020, 08:00 ET Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Aug 17, 2020, 08:00 ET Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Aug 05, 2020, 08:00 ET Amplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Jul 20, 2020, 08:00 ET Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Jun 24, 2020, 08:00 ET Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

Jun 08, 2020, 08:00 ET Amplyx Pharmaceuticals Expands Executive Leadership Team

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in...

May 19, 2020, 08:00 ET Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised ...

May 19, 2020, 08:00 ET Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million

Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised ...

Apr 29, 2020, 08:00 ET Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group's Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

Amplyx Pharmaceuticals, a clinical stage biotech company developing innovative therapies for debilitating and life-threatening diseases in patients...

Sep 24, 2019, 08:00 ET Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...

Sep 16, 2019, 08:00 ET Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...

Sep 16, 2019, 08:00 ET Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...

Sep 09, 2019, 08:00 ET FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients...

Apr 12, 2019, 08:00 ET Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that three posters from the...

Feb 11, 2019, 08:00 ET FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that the U.S. Food and Drug...

Nov 13, 2018, 08:00 ET Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the first patient has been ...

Jun 07, 2018, 08:00 ET Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that Amplyx and its...

Jun 05, 2018, 08:00 ET Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that the company's president...

Apr 30, 2018, 02:15 ET Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that preclinical data...

Mar 19, 2018, 08:40 ET Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, including deadly fungal pathogens, today...

Jan 08, 2018, 08:00 ET Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference

Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, with a near-term focus on deadly fungal...

Oct 09, 2017, 08:00 ET Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017

Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented...

Sep 21, 2017, 08:00 ET Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017

Amplyx Pharmaceuticals, a biotechnology company developing novel antimicrobial agents for life-threatening fungal infections, today announced that...